APA (7th ed.) Citation

Seidah, N. G. (2013). Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Current pharmaceutical design, 19(17), 3161. https://doi.org/10.2174/13816128113199990313

Chicago Style (17th ed.) Citation

Seidah, Nabil G. "Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and Other Pathologies." Current Pharmaceutical Design 19, no. 17 (2013): 3161. https://doi.org/10.2174/13816128113199990313.

MLA (9th ed.) Citation

Seidah, Nabil G. "Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and Other Pathologies." Current Pharmaceutical Design, vol. 19, no. 17, 2013, p. 3161, https://doi.org/10.2174/13816128113199990313.